-+ 0.00%
-+ 0.00%
-+ 0.00%
In a post-mortem analysis of the REDEFINE 1 trial announced at Obesity Week 2026, Novo Nordisk's Cagrisema achieved an average weight loss of 25% among early responders.
Share
Listen to the news
In a post-mortem analysis of the REDEFINE 1 trial announced at Obesity Week 2026, Novo Nordisk's Cagrisema achieved an average weight loss of 25% among early responders.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending